Extensive review of Abbott Laboratories’s "entire" oncology pipeline to date.

Extensive review of Abiogen Pharma SpA’s "entire" oncology pipeline to date.

Extensive review of Adherex Technologies Inc’s "entire" oncology pipeline to date.

Extensive review of Aeterna Zentaris Inc.’s "entire" oncology pipeline to date.

Extensive review of Affymax Inc’s "entire" oncology pipeline to date.

Extensive review of Agensys Inc’s "entire" oncology pipeline to date.

Extensive review of Alfacell Corporation’s "entire" oncology pipeline to date.

Extensive review of Ambit Biosciences Corporation’s "entire" oncology pipeline to date.

Extensive review of Amgen Inc.’s "entire" oncology pipeline to date.

The ultimate tool for serious players who would like to understand the current competitive field in cancer drug development among anti-angiogenic and vascular targeting agents.

In this Analytical Tool, BioSeeker Group brings light and understanding of the whole industrial endeavor in apoptosis as cancer therapeutic target.

The ultimate tool for serious players who would like to understand the current competitive field in cancer vaccine development.

Understand the clinical and strategic challenges towards the commercialization of drugs in lung cancer treatments.

A unique tool for analyzing the complex competitive pressure within the different fields of leukemia therapeutics.

A unique tool for analyzing the vast amount of strategic possibilities that have emerged in lymphoma R&D and business development.

A unique tool for analyzing the complex competitive pressure within the field of prostate cancer.

This report offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in melanoma R&D.

"Analytical Tool - Targeted Therapeutics: Non-Small Cell Lung Cancer " offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in non-small cell lung cancer R&D and business development.

A unique tool for analyzing the vast amount of strategic possibilities that have emerged in antibody R&D and business development in oncology.

A unique tool for analyzing the vast amount of strategic possibilities that have emerged in cancer immunotherapy.

The ultimate tool for serious players who would like to understand the current competitive field in breast cancer drug development.

A unique tool for analyzing the vast amount of strategic possibilities that have emerged in colorectal R&D and business development.

Extensive review of Angiogene Pharmaceuticals Ltd’s "entire" oncology pipeline to date.

There are today more than 200 anti-angiogenic/vascular disruptive/vascular targeting agents drugs in oncology, from early preclinical to marketed drugs. Angiogenesis in Oncology: Drug Pipeline Update lists all drugs and gives you a progress analysis

Extensive review of AnorMED Inc.’s "entire" oncology pipeline to date.

Today, there are more than 190 companies plus partners developing more than 430 antibody based oncology drugs in more than 770 developmental projects. In all targeting around 50 different cancer indications. The number of antibody targets has increased